Recent Updates
Recently added Catalysts
VERA

Vera Therapeutics to Participate in the Jefferies Virtual Healthcare Conference

Key Takeaway: SOUTH SAN FRANCISCO, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ: VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that

Full Press Release Details

SOUTH SAN FRANCISCO, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ: VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that management will provide a corporate presentation and participate in one-on-one investor meetings at the Jefferies Virtual Healthcare Conference, which is taking place June 1-4, 2021.
Presentation details:
Date: Friday, June 4, 2021
Time: 9:00 AM PT (12:00 PM ET)
Presenter: Marshall Fordyce, MD, CEO and Founder of Vera
A live webcast of the presentation can be accessed by visiting the investor relations section of the Company’s website, www.veratx.com. A replay of the webcast will also be available and archived on the site for 90 days following the presentation date.
About Vera Therapeutics
Vera Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Vera’s lead program is atacicept, a fusion protein that is in development for IgA nephropathy, a disease with high unmet medical need and no approved therapies. In addition, Vera is evaluating additional diseases where atacicept’s reduction of autoantibodies may prove medically useful, including lupus nephritis (LN), a severe renal manifestation of systemic lupus erythematosus (SLE). For more information please visit www.veratx.com.
Greig Communications, Inc.
Last updated: May 27, 2021